
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Share your thoughts on the 25th anniversary of Pharm Exec and the evolution of the industry
Now it's your turn:
Pharmaceutical Executive's dedicated readers share what they believe are the industry's turning points and milestones over the past 25 years, as well as what they're looking forward to in the next 25 years.






